BSE Code - 500087
Face Value - Rs 2.00
Group - BSE 'A'
Shareholding pattern - (a)Promoters - 36.80%
(b)Institutions - 35.86%
(c)Non-Institutions - 26.23%
One year High-Low - Rs 575.20 - Rs 366.70
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
Cipla, a global pharmaceutical company, has launched Serroflo, its Salmeterol/Fluticasone MDI, in Germany and Sweden. With this launch, Cipla opens the door for new, highly efficient treatments in the European healthcare market. Serroflo will substantially improve the affordability of Fixed Combinations in Europe and help manage health costs for respiratory treatment.
In Germany the new product is distributed under the name ‘Serroflo’, whereas in Sweden the combination is launched as ‘Salmeterol/Fluticasone Cipla’. Serroflo and Salmeterol/Fluticasone Cipla will be available in a pMDI with HFA propellant in two strengths - 120 doses of 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone.
Current stock price is Rs 557.40, up by 27.70 points from its previous closing of Rs 529.70 on the BSE.
No comments:
Post a Comment